Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor-derived virus-specific T-cell infusion generated by CCS for refractory viral infections in immunocompromised patients
MOH_2026-08-05_016969Phase 2Not yet recruiting
- Sponsor
- היחידה להשתלות מח עצם, המערך ההמטולוגי- אונקולוגי
- Start
- Mar 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CCS-1000 in cytomegalovirus disease (CMV), Epstein-Barr virus infection, adenoviral infection and 2 more, sponsored by היחידה להשתלות מח עצם, המערך ההמטולוגי- אונקולוגי. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
CCS-1000
03
Conditions
cytomegalovirus disease (CMV)Epstein-Barr virus infectionadenoviral infectionBK polyomavirus infectionJC polyomavirus infection
Beyond the preview
Go deeper on MOH_2026-08-05_016969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-05_016969.